263 related articles for article (PubMed ID: 12458143)
1. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; López M; Royo G
Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Rodriguez Díaz JC; López M; Ruiz M; Royo G
Int J Antimicrob Agents; 2003 Jun; 21(6):585-8. PubMed ID: 12791475
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; Climent A; Royo G
Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270
[TBL] [Abstract][Full Text] [Related]
6. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid.
Escribano I; Rodríguez JC; Llorca B; García-Pachon E; Ruiz M; Royo G
Chemotherapy; 2007; 53(6):397-401. PubMed ID: 17934259
[TBL] [Abstract][Full Text] [Related]
7. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.
Rodríguez JC; Cebrián L; López M; Ruiz M; Jiménez I; Royo G
J Antimicrob Chemother; 2004 Mar; 53(3):441-4. PubMed ID: 14963069
[TBL] [Abstract][Full Text] [Related]
8. Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis.
Rodriguez Díaz JC; Ruiz M; López M; Royo G
Int J Antimicrob Agents; 2003 Apr; 21(4):354-6. PubMed ID: 12672583
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
[TBL] [Abstract][Full Text] [Related]
10. Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
García-Tapia A; Rodríguez JC; Ruiz M; Royo G
Chemotherapy; 2004 Nov; 50(5):211-3. PubMed ID: 15523179
[TBL] [Abstract][Full Text] [Related]
11. Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Browne FA; Clark C; Bozdogan B; Dewasse BE; Jacobs MR; Appelbaum PC
Int J Antimicrob Agents; 2002 Aug; 20(2):93-9. PubMed ID: 12297357
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL
Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
[TBL] [Abstract][Full Text] [Related]
14. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Leroi MJ; Siarakas S; Gottlieb T
Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):72-4. PubMed ID: 11913510
[No Abstract] [Full Text] [Related]
15. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
17. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Heinemann B; Wisplinghoff H; Edmond M; Seifert H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2211-3. PubMed ID: 10898706
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Sulochana S; Rahman F; Paramasivan CN
J Chemother; 2005 Apr; 17(2):169-73. PubMed ID: 15920901
[TBL] [Abstract][Full Text] [Related]
19. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
